LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Ultrasound-guided orthotopic implantation of murine pancreatic ductal adenocarcinoma

    Hay, Ceire A / Sor, Rina / Flowers, Ahron J / Clendenin, Cynthia / Byrne, Katelyn T

    Journal of visualized experiments. 2019 Nov. 19, , no. 153

    2019  

    Abstract: The recent success of immune checkpoint blockade in melanoma and lung adenocarcinoma has galvanized the field of immuno-oncology as well as revealed the limitations of current treatments, as the majority of patients do not respond to immunotherapy. ... ...

    Abstract The recent success of immune checkpoint blockade in melanoma and lung adenocarcinoma has galvanized the field of immuno-oncology as well as revealed the limitations of current treatments, as the majority of patients do not respond to immunotherapy. Development of accurate preclinical models to quickly identify novel and effective therapeutic combinations are critical to address this unmet clinical need. Pancreatic ductal adenocarcinoma (PDA) is a canonical example of an immune checkpoint blockade resistant tumor with only 2% of patients responding to immunotherapy. The genetically engineered KrasG12D+/-;Trp53R172H+/-;Pdx-1 Cre (KPC) mouse model of PDA recapitulates human disease and is a valuable tool for assessing therapies for immunotherapy resistant in the preclinical setting, but time to tumor onset is highly variable. Surgical orthotopic tumor implantation models of PDA maintain the immunobiological hallmarks of the KPC tissue-specific tumor microenvironment (TME) but require a time-intensive procedure and introduce aberrant inflammation. Here, we use an ultrasound-guided orthotopic tumor implantation model (UG-OTIM) to non-invasively inject KPC-derived PDA cell lines directly into the mouse pancreas. UG-OTIM tumors grow in the endogenous tissue site, faithfully recapitulate histological features of the PDA TME, and reach enrollment-sized tumors for preclinical studies by four weeks after injection with minimal seeding on the peritoneal wall. The UG-OTIM system described here is a rapid and reproducible tumor model that may allow for high throughput analysis of novel therapeutic combinations in the murine PDA TME.
    Keywords adenocarcinoma ; animal models ; cell lines ; genetic engineering ; histology ; human diseases ; immunotherapy ; inflammation ; lungs ; melanoma ; mice ; pancreas ; patients ; sowing ; ultrasonography
    Language English
    Dates of publication 2019-1119
    Size p. e60497.
    Publishing place Journal of Visualized Experiments
    Document type Article
    ZDB-ID 2259946-0
    ISSN 1940-087X
    ISSN 1940-087X
    DOI 10.3791/60497
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article ; Online: Ultrasound-Guided Orthotopic Implantation of Murine Pancreatic Ductal Adenocarcinoma.

    Hay, Ceire A / Sor, Rina / Flowers, Ahron J / Clendenin, Cynthia / Byrne, Katelyn T

    Journal of visualized experiments : JoVE

    2019  , Issue 153

    Abstract: The recent success of immune checkpoint blockade in melanoma and lung adenocarcinoma has galvanized the field of immuno-oncology as well as revealed the limitations of current treatments, as the majority of patients do not respond to immunotherapy. ... ...

    Abstract The recent success of immune checkpoint blockade in melanoma and lung adenocarcinoma has galvanized the field of immuno-oncology as well as revealed the limitations of current treatments, as the majority of patients do not respond to immunotherapy. Development of accurate preclinical models to quickly identify novel and effective therapeutic combinations are critical to address this unmet clinical need. Pancreatic ductal adenocarcinoma (PDA) is a canonical example of an immune checkpoint blockade resistant tumor with only 2% of patients responding to immunotherapy. The genetically engineered Kras
    MeSH term(s) Animals ; Carcinoma, Pancreatic Ductal/diagnostic imaging ; Carcinoma, Pancreatic Ductal/pathology ; Cell Line, Tumor ; Disease Models, Animal ; Female ; Humans ; Mice ; Mice, Inbred C57BL ; Pancreatic Neoplasms/diagnostic imaging ; Pancreatic Neoplasms/pathology ; Tumor Microenvironment ; Ultrasonography, Interventional/methods ; Xenograft Model Antitumor Assays/methods ; Pancreatic Neoplasms
    Language English
    Publishing date 2019-11-19
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Video-Audio Media
    ZDB-ID 2259946-0
    ISSN 1940-087X ; 1940-087X
    ISSN (online) 1940-087X
    ISSN 1940-087X
    DOI 10.3791/60497
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer.

    Kemp, Samantha B / Cheng, Noah / Markosyan, Nune / Sor, Rina / Kim, Il-Kyu / Hallin, Jill / Shoush, Jason / Quinones, Liz / Brown, Natalie V / Bassett, Jared B / Joshi, Nikhil / Yuan, Salina / Smith, Molly / Vostrejs, William P / Perez-Vale, Kia Z / Kahn, Benjamin / Mo, Feiyan / Donahue, Timothy R / Radu, Caius G /
    Clendenin, Cynthia / Christensen, James G / Vonderheide, Robert H / Stanger, Ben Z

    Cancer discovery

    2022  Volume 13, Issue 2, Page(s) 298–311

    Abstract: Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, ...

    Abstract Mutations in the KRAS oncogene are found in more than 90% of patients with pancreatic ductal adenocarcinoma (PDAC), with Gly-to-Asp mutations (KRASG12D) being the most common. Here, we tested the efficacy of a small-molecule KRASG12D inhibitor, MRTX1133, in implantable and autochthonous PDAC models with an intact immune system. In vitro studies validated the specificity and potency of MRTX1133. In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14 days. Concomitant with tumor cell apoptosis and proliferative arrest, drug treatment led to marked shifts in the tumor microenvironment (TME), including changes in fibroblasts, matrix, and macrophages. T cells were necessary for MRTX1133's full antitumor effect, and T-cell depletion accelerated tumor regrowth after therapy. These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models, providing a rationale for clinical testing and a platform for further investigation of combination therapies.
    Significance: Pharmacologic inhibition of KRASG12D in pancreatic cancer models with an intact immune system stimulates specific, potent, and durable tumor regressions. In the absence of overt toxicity, these results suggest that this and similar inhibitors should be tested as potential, high-impact novel therapies for patients with PDAC. See related commentary by Redding and Grabocka, p. 260. This article is highlighted in the In This Issue feature, p. 247.
    MeSH term(s) Humans ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics ; Pancreatic Neoplasms/pathology ; Carcinoma, Pancreatic Ductal/drug therapy ; Carcinoma, Pancreatic Ductal/genetics ; Carcinoma, Pancreatic Ductal/pathology ; Mutation ; Cell Line, Tumor ; Proto-Oncogene Proteins p21(ras)/genetics ; Tumor Microenvironment ; Pancreatic Neoplasms
    Chemical Substances KRASG12D inhibitor MRTX1133 ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Language English
    Publishing date 2022-12-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-22-1066
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer.

    Wasko, Urszula N / Jiang, Jingjing / Dalton, Tanner C / Curiel-Garcia, Alvaro / Edwards, A Cole / Wang, Yingyun / Lee, Bianca / Orlen, Margo / Tian, Sha / Stalnecker, Clint A / Drizyte-Miller, Kristina / Menard, Marie / Dilly, Julien / Sastra, Stephen A / Palermo, Carmine F / Hasselluhn, Marie C / Decker-Farrell, Amanda R / Chang, Stephanie / Jiang, Lingyan /
    Wei, Xing / Yang, Yu C / Helland, Ciara / Courtney, Haley / Gindin, Yevgeniy / Muonio, Karl / Zhao, Ruiping / Kemp, Samantha B / Clendenin, Cynthia / Sor, Rina / Vostrejs, William P / Hibshman, Priya S / Amparo, Amber M / Hennessey, Connor / Rees, Matthew G / Ronan, Melissa M / Roth, Jennifer A / Brodbeck, Jens / Tomassoni, Lorenzo / Bakir, Basil / Socci, Nicholas D / Herring, Laura E / Barker, Natalie K / Wang, Junning / Cleary, James M / Wolpin, Brian M / Chabot, John A / Kluger, Michael D / Manji, Gulam A / Tsai, Kenneth Y / Sekulic, Miroslav / Lagana, Stephen M / Califano, Andrea / Quintana, Elsa / Wang, Zhengping / Smith, Jacqueline A M / Holderfield, Matthew / Wildes, David / Lowe, Scott W / Badgley, Michael A / Aguirre, Andrew J / Vonderheide, Robert H / Stanger, Ben Z / Baslan, Timour / Der, Channing J / Singh, Mallika / Olive, Kenneth P

    Nature

    2024  

    Abstract: Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS ... ...

    Abstract Broad-spectrum RAS inhibition has the potential to benefit roughly a quarter of human patients with cancer whose tumours are driven by RAS mutations
    Language English
    Publishing date 2024-04-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 120714-3
    ISSN 1476-4687 ; 0028-0836
    ISSN (online) 1476-4687
    ISSN 0028-0836
    DOI 10.1038/s41586-024-07379-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma.

    Wasko, Urszula N / Jiang, Jingjing / Curiel-Garcia, Alvaro / Wang, Yingyun / Lee, Bianca / Orlen, Margo / Drizyte-Miller, Kristina / Menard, Marie / Dilly, Julien / Sastra, Stephen A / Palermo, Carmine F / Dalton, Tanner / Hasselluhn, Marie C / Decker-Farrell, Amanda R / Chang, Stephanie / Jiang, Lingyan / Wei, Xing / Yang, Yu C / Helland, Ciara /
    Courtney, Haley / Gindin, Yevgeniy / Zhao, Ruiping / Kemp, Samantha B / Clendenin, Cynthia / Sor, Rina / Vostrejs, Will / Amparo, Amber A / Hibshman, Priya S / Rees, Matthew G / Ronan, Melissa M / Roth, Jennifer A / Bakir, Basil / Badgley, Michael A / Chabot, John A / Kluger, Michael D / Manji, Gulam A / Quintana, Elsa / Wang, Zhengping / Smith, Jacqueline A M / Holderfield, Matthew / Wildes, David / Aguirre, Andrew J / Der, Channing J / Vonderheide, Robert H / Stanger, Ben Z / Singh, Mallika / Olive, Kenneth P

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. However, the impact of inhibiting RAS functions in normal tissues is not known. RMC-7977 is a highly ... ...

    Abstract Broad-spectrum RAS inhibition holds the potential to benefit roughly a quarter of human cancer patients whose tumors are driven by RAS mutations. However, the impact of inhibiting RAS functions in normal tissues is not known. RMC-7977 is a highly selective inhibitor of the active (GTP-bound) forms of KRAS, HRAS, and NRAS, with affinity for both mutant and wild type (WT) variants. As >90% of human pancreatic ductal adenocarcinoma (PDAC) cases are driven by activating mutations in
    Language English
    Publishing date 2023-12-04
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.12.03.569791
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top